WO2001041703A3 - Method for treating allergic diseases - Google Patents

Method for treating allergic diseases Download PDF

Info

Publication number
WO2001041703A3
WO2001041703A3 PCT/US2000/032461 US0032461W WO0141703A3 WO 2001041703 A3 WO2001041703 A3 WO 2001041703A3 US 0032461 W US0032461 W US 0032461W WO 0141703 A3 WO0141703 A3 WO 0141703A3
Authority
WO
WIPO (PCT)
Prior art keywords
allergic disease
allergic
present
individual
allergic diseases
Prior art date
Application number
PCT/US2000/032461
Other languages
French (fr)
Other versions
WO2001041703A2 (en
Inventor
Erik Wallen
Pope Mosley
Original Assignee
Univ New Mexico
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New Mexico filed Critical Univ New Mexico
Priority to AU32633/01A priority Critical patent/AU3263301A/en
Publication of WO2001041703A2 publication Critical patent/WO2001041703A2/en
Publication of WO2001041703A3 publication Critical patent/WO2001041703A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides methods for treating an allergic disease in which an effective amount of heat shock protein-antigen complex is administered to an individual, such as a human. The method of the present invention may be used either to prevent an individual from having an allergic reaction to an allergic disease or to reduce the effects of an allergic disease in an individual already suffering from the allergic disease. The present invention also provides heat shock protein-peptide-antigen-hybrid complexes and methods for using such complexes to treat allergic diseases.
PCT/US2000/032461 1999-12-07 2000-11-29 Method for treating allergic diseases WO2001041703A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU32633/01A AU3263301A (en) 1999-12-07 2000-11-29 Method for treating allergic diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45459699A 1999-12-07 1999-12-07
US09/454,596 1999-12-07

Publications (2)

Publication Number Publication Date
WO2001041703A2 WO2001041703A2 (en) 2001-06-14
WO2001041703A3 true WO2001041703A3 (en) 2002-01-17

Family

ID=23805279

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/032461 WO2001041703A2 (en) 1999-12-07 2000-11-29 Method for treating allergic diseases

Country Status (2)

Country Link
AU (1) AU3263301A (en)
WO (1) WO2001041703A2 (en)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BLACHERE ET AL.: "Immunization with gp96 heat shock proteins isolated from tumors or influenza virus infected cell elicits MHC restricted, antigen- specific cytotoxic T lymphocyted against the corresponding cells/antigens", J. CELLULAR BIOCHEM., 1993, SUPPLEMENT 17D, KEYSTONE SYMPOSIA ON MOLECULAR AND CELLULAR BIOLOGY, 13 March 1993 (1993-03-13) - 31 March 1993 (1993-03-31), pages 124, ABSTRACT NO. NZ502, XP002942714 *

Also Published As

Publication number Publication date
WO2001041703A2 (en) 2001-06-14
AU3263301A (en) 2001-06-18

Similar Documents

Publication Publication Date Title
WO2001009118A3 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
AU4239196A (en) Methods for the prevention or treatment of vascular hemorrhaging and alzheimer's disease
WO2004068931A3 (en) Amphiregulin antibodies and their use to treat cancer and psoriasis
MY155218A (en) Small molecules useful in the treatment of inflammatory disease
WO2002002518A3 (en) Compounds to treat alzheimer's disease
WO1999064059A3 (en) Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders
WO2002002520A3 (en) Compounds to treat alzheimer's disease
WO2001078711A3 (en) Pde-v inhibitors for treatment of parkinson's disease
WO2001090129A3 (en) Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono and disaccharide-base compounds
WO2002074337A8 (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
WO2002002512A3 (en) Compounds to treat alzheimer's disease
WO2003099771A3 (en) Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
ATE320803T1 (en) METHOD FOR TREATING ALZHEIMER'S DISEASE
EP1251126A3 (en) Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
EP1178988A4 (en) Compounds and therapeutic methods
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
WO2003034996A3 (en) Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
ZA200003768B (en) Methods and compositions for treating diseases and conditions of the eye.
WO2002039994A3 (en) Methods for the treatment and prevention of urinary stone disease
WO1999048489A3 (en) Melatonin for delaying the onset of alzheimer's disease and for treating or delaying the onset of other amyloidosis-related diseases/disorders
MXPA03003741A (en) Methods and compositions for the treatment of diseases of the eye.
WO2000009098A3 (en) Method for treating ocular neovascular diseases
PT1237562E (en) PROCESS OF PREPARATION OF MYCANYAN EXTRACTS CONTAINING MICANOLIDE AND DIHYDROMICANOLID AND USES IN THE TREATMENT OF PROLIFERATIVE DISEASES
MXPA02000680A (en) Vgf polypeptides and methods of treating vgf-related disorders.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

122 Ep: pct application non-entry in european phase